Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

Key Takeaway: Exelixis has provided an update regarding the Phase 3 STELLAR-303 trial, which is evaluating the efficacy of Zanzalintinib in combination with an immune checkpoint inhibitor for patients suffering from metastatic colorectal cancer. The trial aims to assess the potential benefits of this combination therapy in improving patient outcomes.